Podcast appearances and mentions of jim greenwood

Former President Donald Trump will return to the White House next year. The Washington Post's Michael Scherer explains how Trump won. Then, Jacorie McCall is a Black voter who supports Trump and has worked on past Republican campaigns. He reacts to the victory. And, Axios' Margaret Talev takes a look at Trump's likely policies on issues ranging from immigration to health care to taxes and foreign policy. Plus, Here & Now's Peter O'Dowd reports from Arizona. Finally, former Pennsylvania Rep. Jim Greenwood, co-founder of Pennsylvania Republicans for Harris-Walz, talks about which political messages did and didn't resonate in the battleground state.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Tonight on The Last Word: The Harris campaign barnstorms places Donald Trump won in 2020. Also, Congress has until the end of September to fund the government and avoid a shutdown. And Democrats focus on down ballot races in state legislatures. Fmr. Rep. Jim Greenwood, Mary-Grace Vadalla, PA House Speaker Rep. Joanna McClinton, Rep. Joe Neguse, and Heather Williams join Ali Velshi.

Former Rep. Jim Greenwood (R-PA) talks to Richard Chew about Former Republican Members of Congress for Harris and his recent Heartland Signal op-ed about gun violence (https://heartlandsignal.com/2024/09/05/op-ed-former-republican-congressman-decries-yet-more-senseless-gun-violence). Catch "Chew's Views" with Richard Chew weekdays from 6:00 to 8:00 a.m. Central on WCPT (heartlandsignal.com/wcpt820).

Tonight on The Last Word: President Biden and Vice President Harris make their first joint appearance since Harris became the Democratic presidential nominee. Also, “Republicans for Harris” launches in Pennsylvania. Plus, famous drag queens form the Drag PAC to encourage voting. And a secret recording confirms Donald Trump's links to Project 2025. Christina Greer, Stuart Stevens, Jim Greenwood, BenDeLaCreme, and Steve Benen join Ali Velshi.

For more than 25 years, Jim Greenwood served two healthcare services organizations in a variety of roles that included Chief Financial Officer, Executive Vice President of Corporate Development and as Chief Executive Officer since 2007.    Most recently, Jim joined Vision Source in January 2013 and subsequently retired in November 2019 after a successful transition of ownership from a private equity firm to Essilor of America. Vision Source is the nation's largest network of private practice optometrists with more than 3,200 locations and 16 million annual patient visits.     Connect with Jim on a phone call at 972-489-4997 To join The Mastermind 3 Month Summer Program, use the code 'SUMMERSESSION' at checkout to lock in pre-sale pricing. The Total Patient Care Mastermind Workshop we have created is a simple framework to help optometrists serve their patients fully by combining routine and refractive care with advanced medical optometry. This is for a small group of ODs who are ready to deep dive into a program that will help them elevate, streamline, and watch their practice thrive.  For our listeners, use the code 'EYECODEMEDIA22' for 10% off at check out for our Premiere Billing & Coding bundle or our EyeCode Billing & Coding course. Sharpen your billing and coding skills today and leave no money on the table! Show Sponsors: CooperVision MacuHealth EssilorLuxottica

In this episode, DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability. See omnystudio.com/listener for privacy information.

If you are interested in a custom fitted shotgun, from altering an existing gun or a brand new custom stock, Jim Greenwood is the best in the business and has all of the knowledge and expertise to handle the details. Starting with the fitting or building a pattern stock to the help in choosing a checkering pattern through to the finished job. When you choose Greenwood Custom Stocks, you will spend time in the shop working with your mount, grip configuration and then to the sporting course to shoot targets to ensure the fit.  Jim has built stocks for World Champions, National Champions, US Open winners and so many more successful shooters in clay target sports.

Commissioners Donna Shalala and Jim Greenwood give testimony to the House Committee on Energy & Commerce This hearing took place on February 12, 2016. See here for more information. 

  Gun fit is one of the most important aspects of any shooters game and no one understands this more than Jim Greenwood.  Jim joins us to discuss the importance of proper gun fit, what proper gun fit is and what it should look like, custom stocks and much more!   Mike Luongo joins us for Questions for the Coaches and gives us some of his excellent knowledge to some really great questions from the fans!  Listen to another great informative episode that should go to your memory bank!https://greenwoodcustomstocks.comhttps://www.gameboreus.comhttps://www.reranger.comhttps://negrinicases.com/the-dead-pair/https://www.atlastraps.comhttps://barepelt.com

In this episode of On Record PR, Executive Vice President Sarah Larson goes on record with James Greenwood, senior policy advisor at DLA Piper, retired CEO of the Biotechnology Innovation Organization, and former congressman representing Bucks County, Pennsylvania. Learn more Jim Greenwood started his career as a social worker focusing on abused and neglected children in 1980. At the age of 29, he was elected to the Pennsylvania House of Representatives and six years later to the state Senate. In 1992, he was elected to Congress and would go on to represent Pennsylvania's eighth congressional district for six terms from 1993 to 2005. In 2005, Jim voluntarily left Congress to serve as the president and CEO of the Biotechnology Innovation Organization. After 15 years at the helm of BIO, he recently joined DLA Piper where he now chairs the Life Sciences, Health, Policy and Regulatory Group.

The diversity of our adaptive immune system is why people are reacting so differently to the novel coronavirus. No two people present the virus the exact same way to their immune systems. We’ve evolved in this way as humans to ensure no virus can eradicate our species. Hosted by Jim Greenwood.

One day before 16-year-old Izzy Thorpe-Wall takes her first dose of Vertex’s stunning Cystic Fibrosis breakthrough, Thorpe and her mother, Clare, open up about their emotional journey and one brave girl’s determination to stay healthy long enough to meet this day of her dreams. Hosted by Jim Greenwood.

Alnylam Pharmaceuticals, which take its name from the center and brightest star in Orion’s Belt, is working on an RNAi therapy to destroy the genome of the novel coronavirus — and with it, its ability to replicate and kill. Hosted by Jim Greenwood.

While Swedish climate activist Greta Thunberg has kindled a global dialogue about the ravages of climate change and the role of airline emissions, a Colorado biotech is putting forward a jaw-dropping alternative to flight shaming: actual jet fuel with no carbon footprint. Hosted by Jim Greenwood.

Overcrowded hospitals during the pandemic can pose treatment challenges for patients with other serious illnesses. As Kite Pharma CEO Christi Shaw says, “Cancer doesn’t stop in a crisis.” Neither do her company’s employees, who go to extraordinary lengths to get personalized CAR-T treatments to patients around the world. Hosted by Jim Greenwood.

As biotech researchers work around the clock on a covid vaccine, ill-informed, anti-science anti-vaxxers must be denounced and excoriated in the public square. BIO’s head of infectious disease policy Phyllis Arthur administers a vital dose of vaccine education, because none of us is safe until we all are. Hosted by Jim Greenwood.

Viral pandemics can lead to secondary bacterial infections that kill millions, Dr. Anthony Fauci concluded after studying the 1918 Spanish flu. A century later, COVID and antibiotic resistance are proving to be a lethal combination. What are the biopharma industry and Congress doing to keep your loved ones safe from superbugs? Hosted by Jim Greenwood.

Long before COVID’s arrival, antibiotic-resistance was a quiet global pandemic. Now that secondary bacterial infections are killing so many vulnerable patients in the COVID era, the pressure is growing for policy makers to finally address the antibiotics market failure. A cardiologist-turned-biotech entrepreneur explains why the superbugs always win. Hosted by Jim Greenwood.

Jim Greenwood, President and CEO of the Biotechnology Innovation Organization, and the former long-term congressman from Pennsylvania’s 8th District, joined us as part of Intercontinental Exchange’s ongoing series on the latest information and perspectives on the coronavirus pandemic. Jim shared how the 1,000+ biotech companies, academic institutions, state biotech centers, and other organizations that BIO represents are producing the cures, vaccines, and other protocols required to reopen the nation.                                                      Inside the ICE House: https://www.theice.com/insights/conversations/inside-the-ice-house

Jim Greenwood is President and CEO of the Biotechnology Innovation Organization (BIO) in Washington, D.C., representing over 1,000 biotechnology companies and academic institutions in more than 30 countries worldwide. In this podcast, we discuss how BIO is at the front lines of the battle to find treatments and cures for COVID19, by harnessing the many technological breakthroughs of the last two decades. As well, we discuss the political fallout to the U.S. biopharma sector being caused by high out of pocket expenses, and how best to move forward I order to improve trust between industry, government, and patients. A former member of congress, Jim Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives from 1993 to 2005 when he became BIO’s CEO, and his deep relationships on Capitol Hill and policy expertise have substantially raised BIO’s profile and advocacy work. Under his leadership, he has successfully doubled the size of BIO, as well as grown its international influence on global biotechnology innovation. After a hugely successful tenure as BIO’s CEO, Jim Greenwood announced that he will be stepping down at the end of the 2020 fiscal year.

CBS Audio presents a special program focusing on the impact that the coronavirus has had on American society and what comes next in our fight against the virus. Host Gil Gross interviews legendary sportscaster James Brown, Pulitzer Prize-winning journalist Laurie Garrett and biotech executive Jim Greenwood and more to discuss potential solutions to the current situation.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Show Partner: CooperVision Citations: CooperVision data on file 2015. 95% of wearers who say health is important are willing to pay more for contact lenses that ensure eye health. December 2015 contact lens wearer survey, n=564. Cooper Cost Conversations Mr. Jim Greenwood is the Retired President & Chief Executive Officer of Vision Source®, the largest network of private practice optometrists in North America. Prior to Vision Source, Mr. Greenwood served as CEO for Concentra, a national health care company with more than 1,000 clinicians and 300 locations that delivers a wide range of medical services, including urgent care, occupational medicine, physical therapy, primary care and wellness programs. In addition to his role at Vision Source, Mr. Greenwood serves on the Boards of Directors for Legacy Heart Care, Healthcare Associates of Texas and Concentra. A Baylor University graduate, Mr. Greenwood started his career in healthcare in 1993 when he joined Concentra’s predecessor company as Chief Financial Officer. He is a certified public accountant, serving in the commercial banking industry for seven years after beginning his career in public accounting. He currently serves on the Baylor University Healthcare MBA Program’s Advisory Council.

Shaughnessy and former Congressman Jim Greenwood, CEO of the Biotechnology Innovation Organization, discuss the partisan divide, serving in Congress during an impeachment inquiry, and what biotech and pharma have proposed to address prescription drug prices and help combat the opioid crisis. Follow Jim on Twitter: @JimGreenwoodFollow Shaughnessy on Twitter: @VoteShaughnessy

James C. Greenwood is President and CEO of the Biotechnology Innovation Organization (BIO) in Washington, D.C. BIO represents 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 countries worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, and industrial & environmental biotechnology products. BIO also produces the annual BIO International Convention, the world's largest annual gathering of the biotechnology industry, as well as other major investor and business conferences across the world. Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives from 1993 to 2005. Since  2005, his deep relationships on Capitol Hill and knowledge of politics and policy have substantially raised BIO’s profile and enhanced the organization’s advocacy work. During his time in Congress, he was a senior member of the Energy and Commerce Committee and widely viewed as a leader on health care and the environment. He crafted legislation to reform the Food and Drug Administration, and he led the fight in Congress to allow stem-cell research to be conducted by U.S. scientists to treat disease. From 2001 to 2004, Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee's jurisdiction. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation's infrastructure; and waste and fraud in federal government agencies.

On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

The BIO International Convention, the world’s premier life sciences event, will return to Philadelphia, PA, from June 3-6 and is expected to attract more than 16,000 attendees and 1,800 exhibitors from 67 countries. The theme of this year’s convention is “It Starts with One.” Jim Greenwood, President and CEO of the Biotechnology Innovation Organization talks about the challenges, obstacles and future of biotechnology.

The BIO International Convention, the world’s premier life sciences event, will return to Philadelphia, PA, from June 3-6 and is expected to attract more than 16,000 attendees and 1,800 exhibitors from 67 countries. The theme of this year’s convention is “It Starts with One.” Jim Greenwood, President and CEO of the Biotechnology Innovation Organization talks about the challenges, obstacles and future of biotechnology.

Season 2 Episode 10: BIO 2019 Convention: Insights from BIO CEO Jim Greenwood | Growing Greater From June 3rd-6th, 2019, the largest global event for biotechnology is happening right here in Philadelphia. Greater Philadelphia region’s unparalleled talent pool in the life sciences, biopharmaceuticals, and healthcare space, is just one reason why this momentous event is taking place here in just a few short weeks! In this special episode, we talk all things BIO with Jim Greenwood, president and CEO of this special organization. “BIO” which is an acronym for Biotechnology Innovation Organization is based out of Washington DC and represents biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 countries worldwide. We gathered with a live studio audience at Thomas Jefferson University and Jefferson Health for our behind the scenes look at BIO and the upcoming 2019 BIO International Convention.

You’re a pro at helping clients handle change in their financial plans, but how can you navigate major transitions in your own business? As an entrepreneur and advisor, you have to continue to give clients excellent service even during times of change; today’s guest is very familiar with this professional challenge. Jim Greenwood is a Managing Partner at Blue Sky Lasting Wealth. A CFP with 25 years of experience, he most recently transitioned to IPC Securities and founded BlueSky Lasting Wealth. Listen to the episode to hear what Jim has to say about managing changes — both in your career and in the industry. What You’ll Learn in This Episode: How Jim is handling major changes to his business (1:25) How Jim got into wealth management — and how the landscape is different today (4:10) Meeting high service standards with amazing communication (7:00) Approaching transition and succession plans (13:40) How a financial plan is like a marathon (16:05) The most difficult aspect of advising clients — and how to overcome it (19:50) Combatting clients’ number one concern about referring you to their friends (24:10) Links and Resources: Jim Greenwood Blue Sky Lasting Wealth Quotes by Jim: “Our clients recognize the need for professionals or specialists in all areas of their life – doctors, accountants, mechanics, you name it – and we are that person for them when it comes to their financial situation.” “I didn’t necessarily identify exactly what I wanted to do, but I knew what I didn’t want to do, and that was be in some sort of unionized or corporate situation where all of the hard work I do wouldn’t really be reflected in my level of success.” “I think too many people who might want to call themselves entrepreneurs or businesspeople are afraid to take chances.” Jim not only has 25 years of experience in the business — he is also in the thick of some major changes in his practice, including moving to a new office, transitioning to serve more and more high net worth clients, and working with another advisor on a succession plan. Today he’s sharing his advice for keeping your clients happy while navigating major transitions in your business. Below, we’re sharing three key ideas from this episode: How Jim got into wealth management — and how the landscape is different today Prioritizing values during a succession Meeting hig

  This week we hear from Jim Greenwood, Vice President of Wisdom, on how to live out our core value of fun! Jim shares some of his fun stories from his 23 years with the Village. In his words, “People remember how you make them feel most of all…and laughter elicits that positive environment.” GUEST: Jim Greenwood, Vice President, Wisdom HOSTED BY: Grace Berman and Doug Miller SUBMIT YOUR LISTENER MAIL! Share your leadership advice here. For DaVita teammates, please visit podcast.davitaway.com to learn more about our guests and hosts, and listen to our other episodes. Share your thoughts and comments about our podcast here: https://www.surveymonkey.com/r/DLIPodcastEval. Have an idea on a topic you want to hear in 2019? Share it with us here: https://www.surveymonkey.com/r/2019PodcastTopics  

On this week’s Tech Nation, Moira speaks with Pomona College professor Gary Smith about how we humans are the intelligent ones .. and not computers. He de-hypes our expectations of Artificial Intelligence in “The AI Delusion”. Then on Tech Nation Health, a look at the global biotech industry, its accomplishments and its challenges. Jim Greenwood, the President & CEO of BIO, joins us to cover everything from scientific breakthroughs to plentiful jobs for the non-scientists among us.

On this week’s Tech Nation, Moira speaks with Pomona College professor Gary Smith about how we humans are the intelligent ones .. and not computers. He de-hypes our expectations of Artificial Intelligence in “The AI Delusion”. Then on Tech Nation Health, a look at the global biotech industry, its accomplishments and its challenges. Jim Greenwood, the President & CEO of BIO, joins us to cover everything from scientific breakthroughs to plentiful jobs for the non-scientists among us.

On Tech Nation Health, a look at the global biotech industry, its accomplishments and its challenges. Jim Greenwood, the President & CEO of BIO, joins us to cover everything from scientific breakthroughs to plentiful jobs for the non-scientists among us.

See omnystudio.com/listener for privacy information.

Father of the house encourages us – never, never, never give up!

We're broadcasting live from the Vision Source exchange talking to the CEO and President, Jim Greenwood about healthcare reform and doctor alliances.  Also joining the show are Dr. Bobby Christensen, VP of clinical strategies.

Guest: Jim Greenwood, CEO of BIO Bio and Contact Info Listen (2:49) 2013 - the year the IPO window opened Listen (6:02) What has been your primary concern this year?

There's a touch of class this week on the show. Fresh from the Women's World Cup we're joined by American super athlete Phaidra Knight. Phaidra talks at length about the USA's disappointing exit before the semi-finals. We also talk about the future of women's rugby and what needs to be done to restore the USA to the top. Bruce and Alex discuss DI and we acknowledge the passing of coaching legend Jim Greenwood.